SPON2 Is Upregulated Through Notch Signaling Pathway and Promotes Tumor Progression in Gastric Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Jun 5

PMID 32492954

Citations 16

Authors

Hyeon-Gu Kang

Won-Jin Kim

Myung-Giun Noh

Kyung-Hee Chun

Seok-Jun Kim

Affiliations

Soon will be listed here.

Abstract

Spondin-2 (SPON2) is involved in cancer progression and metastasis of many tumors; however, its role and underlying mechanism in gastric cancer are still obscure. In this study, we investigated the role of SPON2 and related signaling pathway in gastric cancer progression and metastasis. SPON2 expression levels were found to be upregulated in gastric cancer cell lines and patient tissues compared to normal gastric epithelial cells and normal controls. Furthermore, SPON2 silencing was observed to decrease cell proliferation and motility and reduce tumor growth in xenograft mice. Conversely, SPON2 overexpression was found to increase cell proliferation and motility. Subsequently, we focused on regulatory mechanism of SPON2 in gastric cancer. cDNA microarray and in vitro study showed that Notch signaling is significantly correlated to SPON2 expression. Therefore, we confirmed how Notch signaling pathway regulate SPON2 expression using Notch signaling-related transcription factor interaction and reporter gene assay. Additionally, activation of Notch signaling was observed to increase cell proliferation, migration, and invasion through SPON2 expression. Our study demonstrated that Notch signaling-mediated SPON2 upregulation is associated with aggressive progression of gastric cancer. In conclusion, we suggest upregulated SPON2 via Notch signaling as a potential target gene to inhibit gastric cancer progression.

Citing Articles

Kindlin-1 promotes gastric cancer cell motility through the Wnt/β-catenin signaling pathway.

Jang J, Jung J, Kang H, Kim W, Kim W, Lee H Sci Rep. 2025; 15(1):2481.

PMID: 39833319 PMC: 11756408. DOI: 10.1038/s41598-025-86220-7.

Knockdown of IGF2BP2 overcomes cisplatin-resistance in lung cancer through downregulating Spon2 gene.

Zhang S, Dou T, Li H, Yu H, Zhang W, Sun L Hereditas. 2024; 161(1):55.

PMID: 39731162 PMC: 11681704. DOI: 10.1186/s41065-024-00360-w.

Progress and prospects of biomarker-based targeted therapy and immune checkpoint inhibitors in advanced gastric cancer.

Zeng Z, Zhu Q Front Oncol. 2024; 14:1382183.

PMID: 38947886 PMC: 11211377. DOI: 10.3389/fonc.2024.1382183.

The biological functions and related signaling pathways of SPON2.

Zhang J, Liu G, Liu Y, Yang P, Xie J, Wei X Front Oncol. 2024; 13:1323744.

PMID: 38264743 PMC: 10803442. DOI: 10.3389/fonc.2023.1323744.

Comprehensive analysis of the oncogenic and immunological role of SPON2 in human tumors.

Tang J, Huang Q, Li X, Gu S Medicine (Baltimore). 2023; 102(37):e35122.

PMID: 37713832 PMC: 10508437. DOI: 10.1097/MD.0000000000035122.

References

Zhou Y, Zhang G, Wang J, Zheng K, Fu W . Current status of lymph node micrometastasis in gastric cancer. Oncotarget. 2017; 8(31):51963-51969. PMC: 5584304. DOI: 10.18632/oncotarget.17495. View

Szasz A, Lanczky A, Nagy A, Forster S, Hark K, Green J . Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget. 2016; 7(31):49322-49333. PMC: 5226511. DOI: 10.18632/oncotarget.10337. View

Wroblewski L, Peek Jr R, Wilson K . Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev. 2010; 23(4):713-39. PMC: 2952980. DOI: 10.1128/CMR.00011-10. View

Jin X, Zhu Z, Shi Y . Metastasis mechanism and gene/protein expression in gastric cancer with distant organs metastasis. Bull Cancer. 2014; . DOI: 10.1684/bdc.2013.1882. View

Qian X, Li C, Pang B, Xue M, Wang J, Zhou J . Spondin-2 (SPON2), a more prostate-cancer-specific diagnostic biomarker. PLoS One. 2012; 7(5):e37225. PMC: 3352876. DOI: 10.1371/journal.pone.0037225. View

Rahman R, Asombang A, Ibdah J . Characteristics of gastric cancer in Asia. World J Gastroenterol. 2014; 20(16):4483-90. PMC: 4000485. DOI: 10.3748/wjg.v20.i16.4483. View

Aoyama T, Yoshikawa T . Adjuvant therapy for locally advanced gastric cancer. Surg Today. 2017; 47(11):1295-1302. DOI: 10.1007/s00595-017-1493-y. View

Zhang Q, Wang X, Wang J, Cui S, Lou X, Yan B . Upregulation of spondin-2 predicts poor survival of colorectal carcinoma patients. Oncotarget. 2015; 6(17):15095-110. PMC: 4558138. DOI: 10.18632/oncotarget.3822. View

Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M . Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018; 391(10125):1023-1075. PMC: 5879496. DOI: 10.1016/S0140-6736(17)33326-3. View

10.

Parry R, Schneider D, Hudson D, Parkes D, Xuan J, Newton A . Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer. Cancer Res. 2005; 65(18):8397-405. DOI: 10.1158/0008-5472.CAN-05-1203. View

11.

Wang L, Liu Y, Yang B, Li P, Cheng X, Xiao C . The extracellular matrix protein mindin attenuates colon cancer progression by blocking angiogenesis via Egr-1-mediated regulation. Oncogene. 2017; 37(5):601-615. DOI: 10.1038/onc.2017.359. View

12.

Yao Y, Ni Y, Zhang J, Wang H, Shao S . The role of Notch signaling in gastric carcinoma: molecular pathogenesis and novel therapeutic targets. Oncotarget. 2017; 8(32):53839-53853. PMC: 5581154. DOI: 10.18632/oncotarget.17809. View

13.

Hemming M, Elias J, Gygi S, Selkoe D . Proteomic profiling of gamma-secretase substrates and mapping of substrate requirements. PLoS Biol. 2008; 6(10):e257. PMC: 2570425. DOI: 10.1371/journal.pbio.0060257. View

14.

Beaugerie L, Svrcek M, Seksik P, Bouvier A, Simon T, Allez M . Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 2013; 145(1):166-175.e8. DOI: 10.1053/j.gastro.2013.03.044. View

15.

Hussain S, Amstad P, Raja K, Ambs S, Nagashima M, BENNETT W . Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res. 2000; 60(13):3333-7. View

16.

Catalano V, Labianca R, Beretta G, Gatta G, De Braud F, Van Cutsem E . Gastric cancer. Crit Rev Oncol Hematol. 2009; 71(2):127-64. DOI: 10.1016/j.critrevonc.2009.01.004. View

17.

Pine S . Rethinking Gamma-secretase Inhibitors for Treatment of Non-small-Cell Lung Cancer: Is Notch the Target?. Clin Cancer Res. 2018; 24(24):6136-6141. PMC: 6295228. DOI: 10.1158/1078-0432.CCR-18-1635. View

18.

Zhang Y, Li Q, Yang X, Fang F, Li J, Wang Y . SPON2 Promotes M1-like Macrophage Recruitment and Inhibits Hepatocellular Carcinoma Metastasis by Distinct Integrin-Rho GTPase-Hippo Pathways. Cancer Res. 2018; 78(9):2305-2317. DOI: 10.1158/0008-5472.CAN-17-2867. View

19.

Lu H, Feng Y, Hu Y, Guo Y, Liu Y, Mao Q . Spondin 2 promotes the proliferation, migration and invasion of gastric cancer cells. J Cell Mol Med. 2019; 24(1):98-113. PMC: 6933360. DOI: 10.1111/jcmm.14618. View

20.

Huang T, Zhou Y, Cheng A, Yu J, To K, Kang W . NOTCH receptors in gastric and other gastrointestinal cancers: oncogenes or tumor suppressors?. Mol Cancer. 2016; 15(1):80. PMC: 5148895. DOI: 10.1186/s12943-016-0566-7. View